News coverage about Neothetics (NASDAQ:NEOT) has trended positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neothetics earned a news impact score of 0.35 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.2947006808172 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Neothetics (NASDAQ NEOT) traded down 0.0312% during midday trading on Friday, hitting $0.3199. 132,263 shares of the company’s stock traded hands. The company’s market capitalization is $4.42 million. The company has a 50 day moving average of $0.43 and a 200-day moving average of $1.34. Neothetics has a 52 week low of $0.30 and a 52 week high of $2.63.

Neothetics (NASDAQ:NEOT) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.20). Equities research analysts predict that Neothetics will post ($0.61) earnings per share for the current year.

Separately, ValuEngine cut shares of Neothetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 27th.

COPYRIGHT VIOLATION NOTICE: “Neothetics (NEOT) Earning Favorable News Coverage, Accern Reports” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at

Neothetics Company Profile

Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

Insider Buying and Selling by Quarter for Neothetics (NASDAQ:NEOT)

Receive News & Stock Ratings for Neothetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics Inc. and related stocks with our FREE daily email newsletter.